Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
STADA: Purchase of a branded product portfolio for the EU markets in Central Europe successfully concluded
- 31/01/2012
Bad Vilbel, January 31, 2012 – Today, on January 31, 2012, STADA Arzneimittel AG successfully concluded the purchase of a branded product portfolio including the associated sales structures for EU markets (including Poland) in Central Europe (see ad hoc release of May 12, 2011 on the assumption of the contract negotiations, the ad hoc update of July 22, 2011 on the signing of the contracts, the ad hoc update of January 1, 2012 on the withdrawal from the purchase of the branded product portfolio in Central Europe as well as the ad hoc update of January 27, 2012 on the renewed signing of the contracts for Central Europe, each published via DGAP).
The branded product portfolio for Central Europe will be consolidated in the STADA Group from February 1, 2012.
STADA had already previously successfully concluded the purchase of the branded product portfolio including the associated sales structures for numerous national markets in Eastern Europe (including Russia and Ukraine) as well as in the Middle East (see ad hoc release of May 12, 2011 on the assumption of contract negotiations, the ad hoc update of July 22, 2011 on the signing of the contracts as well as the ad hoc update of December 30, 2011 on the conclusion of the purchase in Eastern Europe and the Middle East, each published via DGAP).
For more information, please contact:
STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506
e-mail: [email protected]